Cited by 304interferon and immune responsesMultiple Sclerosis Research StudiesGlycosylation and Glycoproteins Research

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)

Runkel, Laura, Meier, Werner, Pepinsky, R. Blake, Karpusas, Michael, Whitty, Adrian, Kimball, Kathleen, Brickelmaier, Margot, Muldowney, Celine, Jones, Wendy, Goelz, Susan E.·1998·Pharmaceutical Research

DOI 10.1023/a:1011974512425

Open this paper in CoChat — free account

Abstract

Purpose Two recombinant IFN-beta products have been approved for the treatment of multiple sclerosis, a glycosylated form with the predicted natural amino acid sequence (IFN-beta-1a) and a non-glycosylated form that has a Met-1 deletion and a Cys-17 to Ser mutation (IFN-beta-1b). The structural basis for activity differences between IFN-beta-1a and IFN-beta-1b, is determined. Methods In vitro antiviral, antiproliferative and immunomodulatory assays were used to directly compare the two IFN-beta products. Size exclusion chromatography (SEC), SDS-PAGE, thermal denaturation, and X-ray crystallography were used to examine structural differences. Results IFN-beta-1a was 10 times more active than IFN-beta-1b with specific activities in a standard antiviral assay of 20 x 10(7) IU/mg for IFN-beta-1a and 2 x 10(7) IU/mg for IFN-beta-1b. Of the known structural differences between IFN-beta-1a and IFN-beta-1b, only glycosylation affected in vitro activity. Deglycosylation of IFN-beta-1a produced a decrease in total activity that was primarily caused by the formation of an insoluble disulfide-linked IFN precipitate. Deglycosylation also resulted in an increased sensitivity to thermal denaturation. SEC data for IFN-beta-1b revealed large, soluble aggregates that had reduced antiviral activity (approximated at 0.7 x 10(7) IU/mg). Crystallographic data for IFN-beta-1a revealed that the glycan formed H-bonds with the peptide backbone and shielded an uncharged surface from solvent exposure. C…

Integrity signals

Registry

Crossref · 10.1023/a:1011974512425

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,197
The Interferon System
Stewart, W. E. (1979) · Springer eBooks · doi:10.1007/978-3-7091-3432-0 · Cited by 1,165
GLYCOBIOLOGY
Rademacher, T. W., Parekh, R. B., & Dwek, R. A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004033 · Cited by 1,144
Protein glycosylation
Lis, H., & Sharon, N. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18347.x · Cited by 840
The interferon system. A bird's eye view of its biochemistry.
Sen, G. C., & Lengyel, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42719-6 · Cited by 633
Glycoproteins: what are the sugar chains for?
Paulson, J. C. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90062-5 · Cited by 461
Influence of the Carbohydrate Moiety on the Stability of Glycoproteins
Wang, C., Eufemi, M., Turano, C., & GIARTOSIO, A. (1996) · Biochemistry · doi:10.1021/bi9517704 · Cited by 344

Flagged first, then by citations

Show all 34 references

Sorted by citations

Items 101–200 of 304

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta
van Beers, M. M. C., Sauerborn, M., Gilli, F., Hermeling, S., Brinks, V., Schellekens, H., & Jiskoot, W. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.10.005 · Cited by 37
Multiple Sclerosis: Therapeutic Strategies on the Horizon
Manjunatha, R. T., Habib, S., Sangaraju, S. L., Yepez, D., & Grandes, X. A. (2022) · Cureus · doi:10.7759/cureus.24895 · Cited by 42
The stabilization of biopharmaceuticals: current understanding and future perspectives
Song, J. G., Lee, S. H., & Han, H. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0341-9 · Cited by 36
A role of glycosyl moieties in the stabilization of bitter gourd (Momordica charantia) peroxidase
Fatima, A., & Husain, Q. (2007) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2006.12.007 · Cited by 36
The Rebif® New Formulation Story
Jaber, A., Driebergen, R. J., Giovannoni, G., Schellekens, H., Simsarian, J., & Antonelli, M. (2007) · Drugs in R&D · doi:10.2165/00126839-200708060-00002 · Cited by 35
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
Song, K., Yoon, I., Kim, N. A., Kim, D.-H., Lee, J., Lee, H. J., Lee, S., Choi, S.-H., Choi, M., Kim, H. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096967 · Cited by 35
Recombinant human interferon beta in relapsing–remitting multiple sclerosis: a review of the major clinical trials
Chofflon, M. (2000) · European Journal of Neurology · doi:10.1046/j.1468-1331.2000.00057.x · Cited by 35
Enhanced interferon‐β production by CHO cells through elevated osmolality and reduced culture temperature
Han, Y. K., Koo, T. Y., & Lee, G. M. (2009) · Biotechnology Progress · doi:10.1002/btpr.234 · Cited by 37
Disease-modifying therapies for multiple sclerosis
Corboy, J. R., Goodin, D. S., & Frohman, E. M. (2003) · Current Treatment Options in Neurology · doi:10.1007/s11940-003-0021-0 · Cited by 33
N-linked Glycosylation Is Required for Optimal Function of Kaposi's Sarcoma Herpesvirus–encoded, but Not Cellular, Interleukin 6
Cruz, C. S. D., Lee, Y., Viswanathan, S. R., El-Guindy, A. S., Gerlach, J., Nikiforow, S., Shedd, D. G., Gradoville, L., & Miller, G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031205 · Cited by 34
Treatment of multiple sclerosis with human beta interferon.
Goodin, D. S. (2005) · PubMed · Cited by 34
Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis
Grossberg, S. E., Oger, J. J.-F., Grossberg, L. D., Gehchan, A., & Klein, J. P. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0038 · Cited by 33
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
Creeke, P. I., & Farrell, R. A. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612469264 · Cited by 32
An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products
Meager, A., Dolman, C., Dilger, P., Bird, C., Giovannoni, G., Schellekens, H., Thorpe, R., & Wadhwa, M. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0113 · Cited by 32
IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays
Capra, R., Sottini, A., Cordioli, C., Serana, F., Chiarini, M., Caimi, L., Padovani, A., Bergamaschi, R., & Imberti, L. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.06.006 · Cited by 32
Development and characterization of interleukin-18-loaded biodegradable microspheres
Lagarce, F., Garcion, E., Faisant, N., Thomas, O., Kanaujia, P., Meneï, P., & Benoît, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.07.029 · Cited by 34
An urticarial IgE-mediated reaction to interferon β-1b
Brown, D. L., Login, I. S., Borish, L., & Powers, P. (2001) · Neurology · doi:10.1212/wnl.56.10.1416-a · Cited by 32
Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities
Christen, U., Thuerkauf, R., Stevens, R. M., & Lesslauer, W. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00068-3 · Cited by 32
The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage
Svilenov, H. L., & Winter, G. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.02.018 · Cited by 31
Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach
Katla, S., Yoganand, K. N. R., Hingane, S., Ranjith-Kumar, C. T., Anand, B., & Sivaprakasam, S. (2019) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2019.05.007 · Cited by 31
Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation
Mueller, C., Capelle, M. A. H., Arvinte, T., Seyrek, E., & Borchard, G. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.06.003 · Cited by 31
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics
Barbosa, M. D. F. S., Kumar, S., Loughrey, H. C., & Singh, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.003 · Cited by 30
Structural Mapping of Post-translational Modifications in Human Interleukin-24
Fuson, K. L., Zheng, M., Craxton, M., Pataer, A., Ramesh, R., Chada, S., & Sutton, R. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.036061 · Cited by 30
Interferon-Beta in the Treatment of Multiple Sclerosis
Clanet, M. (2001) · Clinical Drug Investigation · doi:10.2165/00044011-200121040-00009 · Cited by 30
Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications
Naseri, R., Navabi, S. J., Samimi, Z., Mishra, A. P., Nigam, M., Chandra, H., Olatunde, A., Tijjani, H., Morais‐Urano, R. P., & Farzaei, M. H. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00327-y · Cited by 31
Chemical (neo)glycosylation of biological drugs
Walther, R., & Zelikin, A. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.021 · Cited by 29
Study of binding and neutralising antibodies to interferon-? in two groups of relapsing-remitting multiple sclerosis patients
Fern�ndez, O., Mayorga, C., Luque, G., Guerrero, M., Guerrero, R., Leyva, L., de Le�n, A. P., & Blanca, M. (2001) · Journal of Neurology · doi:10.1007/s004150170178 · Cited by 29
Characterization of a soluble ternary complex formed between human interferon‐β‐1a and its receptor chains
Arduini, R. M., Strauch, K. L., Runkel, L., Carlson, M. M., Hronowski, X. L., Foley, S. F., Young, C. N., Cheng, W., Hochman, P. S., & Baker, D. P. (1999) · Protein Science · doi:10.1110/ps.8.9.1867 · Cited by 28
Self-citation
Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Meléndez‐Torres, G. J., Auguste, P., Armoiry, X., Maheswaran, H., Court, R. A., Madan, J. J., Kan, A., Lin, S., Counsell, C. E., Patterson, J. V., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21520 · Cited by 27
Overexpression of Recombinant Human Beta Interferon (rhINF-β) in Periplasmic Space of Escherichia coli.
Morowvat, M. H., Babaeipour, V., Rajabi-Memari, H., Vahidi, H., & Maghsoudi, N. (2014) · Europe PMC (PubMed Central) · Cited by 27
Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein
Ceaglio, N., Etcheverrigaray, M., Kratje, R. B., & Oggero, M. (2010) · Biochimie · doi:10.1016/j.biochi.2010.04.004 · Cited by 27
Targeting and post‐translational processing of human α1‐antichymotrypsin in BY‐2 tobacco cultured cells†
Benchabane, M., Saint‐Jore‐Dupas, C., Bardor, M., Faye, L. J.-Y., Michaud, D., & Gomord, V. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00382.x · Cited by 27
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice
Kijanka, G., Jiskoot, W., Schellekens, H., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0992-9 · Cited by 26
Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control
Jedrzejewski, P., del Val, I. J., Polizzi, K. M., & Kontoravdi, C. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.4 · Cited by 27
Development of resistance to biologic therapies with reference to IFN-β.
Farrell, R., Marta, M., Gaeguta, A., Souslova, V., Giovannoni, G., & Creeke, P. (2012) · Rheumatology · doi:10.1093/rheumatology/ker445 · Cited by 23
Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes
Singh, S., Singh, A., Aziz, M. A., Waheed, S. M., Bhat, R., & Bhatnagar, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.020 · Cited by 26
Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation
Fung, E., Kang, L., Sapashnik, D., Benard, S., Sievers, A., Liu, Y., Yan, G. G., Zhou, J. W., Rodriguez, L., Ma, W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87959-5 · Cited by 24
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β
Hegen, H., Auer, M., & Deisenhammer, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1094055 · Cited by 25
Erythropoiesis-Stimulating Agents
Elliott, S. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-7073-2_4 · Cited by 24
Biological standardization of human interferon beta: Establishment of a replacement world health organization international biological standard for human glycosylated interferon beta
Meager, A., & Das, R. G. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.007 · Cited by 24
Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
Abdolvahab, M. H., Fazeli, A., Halim, L. A., Sediq, A. S., Fazeli, M. R., & Schellekens, H. (2016) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0108 · Cited by 24
Site-Directed Glycosylation of Peptide/Protein with Homogeneous O-Linked Eukaryotic N-Glycans
Wu, Z., Jiang, K., Zhu, H. J., Ma, C., Yu, Z. J., Li, L., Guan, W., Liu, Y., Zhu, H., Chen, Y., et al. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00385 · Cited by 24
Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
Monzani, F. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s476 · Cited by 24
Improving Biopharmaceutical Safety Through Verification‐Based Quality Control
Yu, Y. B., Taraban, M. B., Wang, W., & Briggs, K. T. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.08.010 · Cited by 23
Comparative Study on the Characterization of Myofibrillar Proteins from Tilapia, Golden Pompano and Skipjack Tuna
Wang, H., Pei, Z., Xue, C., Cao, J., Shen, X., & Li, C. (2022) · Foods · doi:10.3390/foods11121705 · Cited by 23
Interferon receptor expression in multiple sclerosis patients
Oliver‐Martos, B., Mayorga, C., Fernández, V., Leyva, L., León, A., Luque, G., López, J. C., Tamayo, J. A., Pinto-Medel, M. J., de Ramón, E., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.010 · Cited by 23
Prospects in the Total Synthesis of Protein Therapeutics
Chalker, J. M. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12007 · Cited by 23
Expression and characterization of human interferon‐β1 in the methylotrophic yeast Pichia pastoris
Skoko, N., Argamante, B., Kovačević‐Grujičić, N., Tisminetzky, S. G., Glišin, V., & Ljubijankić, G. (2003) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20030065 · Cited by 23
Soluble Human MDA-7/IL-24: Characterization of the Molecular Form(s) Inhibiting Tumor Growth and Stimulating Monocytes
Mumm, J. B., Ekmekçioglu, S., Poindexter, N. J., Chada, S., & Grimm, E. A. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.877 · Cited by 23
External Factors Affecting Protein Aggregation
Wang, W., Li, N., & Speaker, S. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch4 · Cited by 24
Arabinosylation of recombinant human immunoglobulin-based protein therapeutics
Hossler, P., Chumsae, C., Racicot, C., Ouellette, D., Ibraghimov, A. R., Serna, D., Mora, A., McDermott, S., Labkovsky, B., Scesney, S. M., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1294295 · Cited by 25
Influence of glycan modification on IgG1 biochemical and biophysical properties
Pawlowski, J. W., Bajardi-Taccioli, A., Houde, D. J., Feschenko, M. S., Carlage, T., & Kaltashov, I. A. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.061 · Cited by 21
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
Hartung, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802677882 · Cited by 21
High yields of monomeric recombinant β‐interferon from macroporous microcarrier cultures under hypothermic conditions
Tharmalingam, T., Sunley, K., & Butler, M. (2008) · Biotechnology Progress · doi:10.1002/btpr.8 · Cited by 21
BIOTECHNOLOGY: Aggregation of Recombinant Human Botulinum Protein Antigen Serotype C in Varying Solution Conditions: Implications of Conformational Stability for Aggregation Kinetics
Bai, S., Manning, M. C., Randolph, T. W., & Carpenter, J. F. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22345 · Cited by 20
Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory
Sauerborn, M., van Beers, M. M. C., Jiskoot, W., Kijanka, G., Boon, L., Schellekens, H., & Brinks, V. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9783-z · Cited by 20
Recombinant Human Interferon-??-1a (Rebif??) vs Recombinant Interferon-??-1b (Betaseron??) in Healthy Volunteers
Buraglio, M., Trinchard-Lugan, I., Munafo, A., & Macnamee, M. C. (1999) · Clinical Drug Investigation · doi:10.2165/00044011-199918010-00004 · Cited by 20
Identification of interferon-τ isoforms expressed by the peri-implantation goat (Capra hircus) conceptus
Ealy, A. D., Wagner, S. K., Sheils, A. E., Whitley, N. C. C., Kiesling, D. O., Johnson, S., & BARBATO, G. F. (2004) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2004.01.006 · Cited by 20
Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation
Fazeli, A., Abdolvahab, M. H., Shojaosadati, S. A., Schellekens, H., Khalifeh, K., Moosavi‐Movahedi, A. A., & Fazeli, M. R. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0192-x · Cited by 19
Herpesviruses—a rationale for antiviral treatment in multiple sclerosis
Bergström, T. B. (1999) · Antiviral Research · doi:10.1016/s0166-3542(98)00067-9 · Cited by 19
Measured Neutralizing Titers of IFN- β Neutralizing Antibodies (NAbs) Can Depend on the Preparations of IFN- β Used in the Assay
Files, J. G., Hargrove, D., Delute, L., & Cantillon, M. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.0131 · Cited by 19
In VitroAssessment of the Biologic Activity of Interferon Beta Formulations used for the Treatment of Relapsing Multiple Sclerosis
Scagnolari, C., Selvaggi, C., Biase, E. D., Fraulo, M., Dangond, F., & Antonelli, G. (2013) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2013.848815 · Cited by 18
First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis
Johnston, J., & So, T.-Y. (2012) · Drugs · doi:10.2165/11634010-000000000-00000 · Cited by 18
Determination of Carbohydrate Structures N-Linked to Soluble CD154 and Characterization of the Interactions of CD40 with CD154 Expressed in Pichia pastoris and Chinese Hamster Ovary Cells
Khandekar, S. S., Silverman, C., Wells-Marani, J., Bacon, A. M., Birrell, H. C., Brigham-Burke, M. R., DeMarini, D. J., Jonak, Z., Camilleri, P., & Fishman‐Lobell, J. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1501 · Cited by 18
Implications of glycosylation for the development of selected cytokines and their derivatives for medical use
Scapin, G., Çağdaş, E., Grav, L. M., Lewis, N. E., Goletz, S., & Hafkenscheid, L. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108467 · Cited by 19
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
Peyvandi, F., Miri, S., & Garagiola, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591878 · Cited by 17
O-Linked Glycosylation Leads to Decreased Thermal Stability of Interferon Alpha 2b as Measured by Two Orthogonal Techniques
Johnston, M., Frahm, G. E., Li, X., Durocher, Y., & Hefford, M. A. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0402-0 · Cited by 17
Evaluation of the impact of neutralizing antibodies on IFNβ response
Bertolotto, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.02.043 · Cited by 16
Rational design of hyper-glycosylated interferon beta analogs: A computational strategy for glycoengineering
Samoudi, M., Tabandeh, F., Minuchehr, Z., Cohan, R. A., Inanlou, D. N., Khodabandeh, M., & Anvar, M. S. (2014) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2014.12.001 · Cited by 16
The Effects of Dodecyl Maltoside and Sodium Dodecyl Sulfate Surfactants on the Stability and Aggregation of Recombinant Interferon Beta-1b
Abdolvahab, M. H., Fazeli, A., Fazeli, M. R., Brinks, V., & Schellekens, H. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0131 · Cited by 16
Structure and function of the N‐linked glycans of HBP/CAP37/azurocidin: Crystal structure determination and biological characterization of nonglycosylated HBP
Iversen, L. F., Kastrup, J. S., Bjørn, S. E., Wiberg, F. C., Larsen, I. K., Flodgaard, H. J., & Rasmussen, P. B. (1999) · Protein Science · doi:10.1110/ps.8.10.2019 · Cited by 16
Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β
Wadhwa, M., Subramanyam, M., Goelz, S. E., Goyal, J., Jethwa, V., Jones, W. E., Files, J. G., Kramer, D., Bird, C., Dilger, P., et al. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0079 · Cited by 15
Self-citation
Effect Of Benzyl Alcohol on Recombinant Human Interleukin-1 Receptor Antagonist Structure and Hydrogen–Deuterium Exchange
Alford, J. R., Fowler, C. A., Wuttke, D. S., Kerwin, B. A., Latypov, R. F., Carpenter, J. F., & Randolph, T. W. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22601 · Cited by 14
In vitro biological characterization of IFN- -1a major glycoforms
Mastrangeli, R., Rossi, M., Mascia, M., Palinsky, W., Datola, A., Terlizzese, M., & Bierau, H. (2014) · Glycobiology · doi:10.1093/glycob/cwu082 · Cited by 14
GDF15 Analogues Acting as GFRAL Ligands
Santo, A. D., Tarchi, L., Villa, G., Castellini, G., Ricca, V., Squecco, R., Papini, A. M., Real‐Fernández, F., & Rovero, P. (2025) · ChemMedChem · doi:10.1002/cmdc.202400961 · Cited by 14
The role of trehalose for metastable state and functional form of recombinant interferon beta-1b
Fazeli, A., Shojaosadati, S. A., Fazeli, M. R., Khalifeh, K., Ariaeenejad, S., & Moosavi‐Movahedi, A. A. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.11.010 · Cited by 13
Effects of localized interactions and surface properties on stability of protein-based therapeutics
Mills, B. J., & Chadwick, J. S. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12658 · Cited by 13
Fixed drug eruption with interferon‐β‐1b
Tai, Y. J., & Tam, M. M. (2005) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2005.00168.x · Cited by 13
Effect of Culture Conditions on Glycosylation of Recombinant beta-Interferon in CHO Cells
Spearman, M. A., Rodriguez, J., Huzel, N. J., Sunley, K., & Butler, M. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5476-1_11 · Cited by 13
Recombinant Interferon-??-1a*
Wagstaff, A. J., & Goa, K. L. (1998) · BioDrugs · doi:10.2165/00063030-199810060-00005 · Cited by 13
Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples
Cludts, I., Meager, A., Thorpe, R., & Wadhwa, M. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.06.008 · Cited by 12
Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
Lee, C. G., Kim, T., Hong, S., Chu, J., Kang, J. E., Park, H. G., Choi, J. Y., Song, K., Rha, S. Y., Lee, S. H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.608774 · Cited by 12
Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging
Sales, M. D. L. M., Kratje, R. B., Oggero, M., & Ceaglio, N. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.12.016 · Cited by 12
Clinical Aspects of Immunogenicity to Biopharmaceuticals
Malucchi, S., & Bertolotto, A. (2008) · Springer eBooks · doi:10.1007/978-0-387-75841-1_2 · Cited by 12
Neutralizing antibodies to multiple sclerosis treatments.
Rossman, H. S. (2004) · PubMed · Cited by 12
Heterologous interferons synthesis in yeast Pichia pastoris
Padkina, M. V., Parfenova, L. V., Градобоева, А. Е., & Sambuk, E. V. (2010) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683810040083 · Cited by 11
Secreted expression of an active human interferon‐beta (HuIFNβ) in Kluyveromyces lactis
Madhavan, A., & Sukumaran, R. K. (2016) · Engineering in Life Sciences · doi:10.1002/elsc.201500120 · Cited by 11
Assessment of Clinically Relevant Immunogenicity for mAbs; are we Over Reporting ADA?
Hassanein, M., Partridge, M. A. K., Shao, W., & Torri, A. (2020) · Bioanalysis · doi:10.4155/bio-2020-0174 · Cited by 11
N-Glycosylation of Murine IFN- β in a Putative Receptor-Binding Region
Sommereyns, C., & Michiels, T. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.406 · Cited by 11
Cysteine as a Monothiol Reducing Agent to Prevent Copper-Mediated Oxidation of Interferon Beta During PEGylation by CuAAC
Nairn, N. W., Bariola, P. A., Graddis, T. J., VanBrunt, M. P., Wang, A., Li, G., & Grabstein, K. H. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00320 · Cited by 11
Meaningful treatment outcomes in Alzheimer's disease
Burns, A. S. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.471 · Cited by 11
Application of Quality by Design Paradigm to the Manufacture of Protein Therapeutics
del Val, I. J., Philip, M., Exley, K., Sou, S. N., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2012) · InTech eBooks · doi:10.5772/50261 · Cited by 12
Neutralizing antibodies against IFN beta in patients with multiple sclerosis: A comparative study of two cytopathic effect tests (CPE) for their detection
Oliver‐Martos, B., Órpez, T., Mayorga, C., Pinto-Medel, M. J., Leyva, L., Gomez, C. L., Marín, C., Luque, G., Ortega-Pinazo, J., & Fernández, Ó. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.09.005 · Cited by 10
The half-life of the bone-derived hormone osteocalcin is regulated through O-glycosylation in mice, but not in humans
Rifai, O. A., Julien, C., Faubert, D., Lira‐Navarrete, E., Narimatsu, Y., Lacombe, J., Clausen, H., & Ferron, M. (2020) · eLife · doi:10.7554/elife.61174 · Cited by 10
Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
van de Weert, M., & Møller, E. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-75841-1_5 · Cited by 10
Design, construction, and expression of recombinant human interferon beta gene in CHO-s cell line using EBV-based expression system
Tabandeh, F., Shayesteh, M., Ghasemi, F., Yakhchali, B., & Shakibaie, M. (2020) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.283814 · Cited by 9
A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics
Lee, S., Son, W. S., Yang, H. B., Rajasekaran, N., Kim, S.-S., Hong, S., Choi, J., Choi, J. Y., Song, K., & Shin, Y. K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01568 · Cited by 9
Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β
Ji, S.-I., Park, J.-H., You, H.-G., Chi, H., Bang, Y.-W., & Cha, S.-H. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.01.009 · Cited by 9
Improving human interferon‐β production in mammalian cell lines by insertion of an intronic sequence within its naturally uninterrupted gene
Zago, P., Baralle, M., Ayala, Y. M., Skoko, N., Zacchigna, S., Buratti, E., & Tisminetzky, S. G. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20080046 · Cited by 9
Disulfide–bridging PEGylation during refolding for the more efficient production of modified proteins
Ginn, C., Choi, J.-W., & Brocchini, S. (2016) · Biotechnology Journal · doi:10.1002/biot.201600035 · Cited by 9

Authors: Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E.
Affiliations: Biogen (United States) (US)
Corresponding author: Runkel, Laura
ORCID: Whitty, Adrian
Venue: Pharmaceutical Research
Publisher: Springer Science and Business Media LLC
Published: 1998-04
Volume: 15
Issue: 4
Pages: 641-649
ISSN: 0724-8741 (ISSN-L)
1573-904X
DOI: 10.1023/a:1011974512425
OpenAlex: W329292291
Cited by: 304
References: 34
Citations by year: 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 10 · 2020: 11 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 16 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 13
FWCI: 3.46
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Pharmaceutical Research (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
Keywords: interferon-beta, glycosylation, recombinant interferon, multiple sclerosis, antiviral activity, protein stability, thermal denaturation, protein aggregation, disulfide bonds, protein structure
MeSH terms: Interferon beta-1a, Interferon beta-1b, Adjuvants, Immunologic, Antiviral Agents, Base Sequence, Cell Division, Cell Line, Cysteine, Encephalomyocarditis virus, Glycosylation, Humans, Major Histocompatibility Complex, Molecular Sequence Data, Mutation, Recombinant Proteins, Serine, Interferon-beta, Cardiovirus Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks